Desfoxine Dosage/Direction for Use

Recommended Dose: Adults: Major depressive disorder: The recommended usual and maintenance dose is 50 mg once daily, with or without food. If dose increases are indicated for individual patients, they should occur gradually and at intervals of not less than 7 days. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be periodically reassessed to determine the need for continued treatment.
Vasomotor symptoms associated with menopause: The recommended dose is 100 mg once daily, with or without food. It is recommended to start at 50 mg/day for up to 7 days, to allow patients to adjust to the medicine before increasing to 100 mg/day.
Pediatric: Safety and effectiveness of Desvenlafaxine in pediatric patients younger than 18 years old have not been established.
Dosage in hepatic impairment: The recommended Desvenlafaxine dosage is 50 mg given once daily. Dosages exceeding 100 mg daily are not recommended.
Dosage in renal impairment: In patient with mild renal impairment, Desvenlafaxine dosage adjustment is not necessary.
In patient with moderate renal impairment (creatinine clearance of 30-50 mL/minute), the recommended dosage is 50 mg given once daily.
In patient with severe renal impairment (creatinine clearance less than 30 mL/minute) or end-stage renal disease, the dosage is 50 mg given every other day.
Dosage in elderly: No dosage adjustment is required solely on the basis of age; however, possible reduced renal clearance of Desvenlafaxine should be considered when determining dose.
Mode of administration: Desvenlafaxine succinate is administered orally once daily with or without food at approximately the same time each day. Extended-release tablet of the drug should be swallowed whole with fluid and not be divided, crushed, chewed, or dissolved.